Bioceres S.A. BIOX 深 滬
等待開盤 09-04 09:30:00 美东时间
2.815
-0.075
-2.60%
華盛通- 最 高2.95
- 今 開2.91
- 成交量 31.24万股
- 最 低 2.81
- 昨 收 2.89
- 總市值 1.70亿
- 52周最高 8.785
- 市盈率 靜 55.09
- 換手率 0.52%
- 52周最低 2.60
- 委 比 -16.38%
- 總股本 6045.28万
- 歷史最高 17.94
- 量 比 0.61
- 振 幅 4.84%
- 歷史最低 2.60
- 每 手 1
- 風險率 1.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected
BioSig Technologies Inc. announced that Proposal No. 1 (The Acquisition Proposal) regarding the merger with Streamex Exchange Corporation has been adjourned pending final NASDAQ approval. The merger transaction closed on May 28, 2025, with 19.99% of BioSig shares already issued to Streamex shareholders. Remaining share issuances require shareholder approval at a later reconvened Special Meeting. The delay does not impact the merger closing, Compa...
09-03 02:59
Bioceres Announces Departure of Chief Commercial Officer
Bioceres Crop Solutions ( ($BIOX) ) has issued an update. Bioceres Crop Solutio...
09-02 21:28
Biomerica Reports Fiscal 2025 Year End Results
Biomerica reported net sales of $5.3 million in Fiscal 2025, slightly lower than FY 2024 due to global tariff uncertainties and product mix shifts. Operating expenses decreased by $1.3 million, achieving a 19% improvement in operating loss to $5.1 million. Strategic growth areas include advancing inFoods® IBS reimbursement pathways, expanding EZ Detect™ and H. pylori sales, and pursuing MENA market opportunities. Key milestones include PLA code i...
08-29 21:12
Top 3 Materials Stocks That Are Set To Fly This Month
The most oversold stocks in the materials sector presents an opportunity to buy...
08-29 19:26
Bioceres Crop Solutions Announces CFO Transition
Bioceres Crop Solutions ( ($BIOX) ) has provided an announcement. Bioceres Crop...
08-21 18:29
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Inc. announced positive feedback from the FDA regarding its planned sNDA submission for expanding the use of IGALMI (dexmedetomidine) for at-home treatment of agitation in bipolar disorder or schizophrenia. The sNDA submission remains on track for Q1 2026. The Company has achieved alignment with the FDA on the regulatory package content and format. IGALMI is currently approved for agitation management in medically supervised ...
08-18 11:00
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio reported financial results for Q2 2025 and key business highlights. Notably, the company completed dosing of Cohort 2 in the upliFT-D study and reported interim data showing continued robust increases in CSF PGRN levels and improved plasma NfL biomarkers. The amended study protocol was submitted to global trial sites and health authorities. Cash runway extends into 1Q 2027. Financials showed $57.6 million in cash, reduced R&D and G&A ...
08-12 11:00
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference
BioXcel Therapeutics, Inc. announced that its CEO, Vimal Mehta, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 12 p.m. ET. The event will be webcast and available for replay for 90 days. The company focuses on developing medicines in neuroscience and immuno-oncology using artificial intelligence.
08-11 11:00
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics announced the completion of the last patient visit in the pivotal Phase 3 SERENITY At-Home clinical trial, evaluating the safety of BXCL501 for treating agitation associated with bipolar disorders or schizophrenia in the home setting. Data from over 2,200 agitation episodes were collected, with results expected this month to support an sNDA for expanding IGALMI's label for at-home use. The trial enrolled over 200 patients acr...
08-01 11:00
Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
BioCardia, Inc. announced that Henry Ford Health in Detroit is enrolling patients with ischemic HFrEF in the CardiAMP HF II trial, a pivotal study for autologous bone marrow-derived mononuclear cell therapy. The trial aims to confirm the safety and efficacy of this therapy, which promotes microvascular repair and improves heart function. CardiAMP HF II is a 250-patient, randomized, multicenter, placebo-controlled study targeting patients on guide...
07-16 12:45
